Comparative Pharmacology
Head-to-head clinical analysis: ALOSETRON HYDROCHLORIDE versus ALOXI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOSETRON HYDROCHLORIDE versus ALOXI.
ALOSETRON HYDROCHLORIDE vs ALOXI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alosetron is a selective antagonist of the serotonin 5-HT3 receptor. By blocking 5-HT3 receptors in the gastrointestinal tract and central nervous system, it reduces visceral hypersensitivity, colonic motility, and intestinal secretions, thereby alleviating symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D).
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
1 mg orally twice daily for 4 weeks; if response is inadequate, increase to 1 mg twice daily for an additional 4 weeks.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
None Documented
None Documented
Clinical Note
moderateRaloxifene + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Fluconazole
Terminal half-life is approximately 1.5–2 hours in healthy volunteers; prolonged in hepatic impairment (up to 2.5 hours) but no significant accumulation with repeated dosing.
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Renal: ~73% (mostly as metabolites), Fecal: ~24%, Biliary: minor; <1% excreted unchanged in urine.
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Category C
Category C
5-HT3 Antagonist
5-HT3 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Raloxifene."